LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies
Movement Disorders2016Vol. 32(3), pp. 423–432
Citations Over TimeTop 10% of 2016 papers
Nicolas Dzamko, Amanda M. Gysbers, Rina Bandopadhyay, Marc Bolliger, A Uchino, Ye Zhao, Masaki Takao, Sandrine Wauters, Wilma D. J. van de Berg, Junko Takahashi‐Fujigasaki, R. Jeremy Nichols, Janice L. Holton, Shigeo Murayama, Glenda M. Halliday
Abstract
Our data show that LRRK2 phosphorylation is reduced with clinical PD, whereas LRRK2 expression is increased in early potential prodromal stages. These results contribute to a better understanding of the role of LRRK2 in idiopathic Parkinson's disease and may aid efforts aimed at therapeutically targeting the LRRK2 protein. © 2016 International Parkinson and Movement Disorder Society.
Related Papers
- → Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease(2014)394 cited
- → Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases(2002)323 cited
- → The neuropathology of genetic Parkinson's disease(2012)313 cited
- → Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders(2022)85 cited
- → Plasma exosomal alpha-synuclein in inherited forms of Parkinson’s disease(2020)